Optimal prevention of VTE in cancer surgery patients with impaired renal function

O.V. Katelnitskaya

National Medical Research Center for Oncology

ORCID: 0000-0002-7777-9943

A.A. Barashev

National Medical Research Center for Oncology

ORCID: 0000-0002-7242-6938

T.V. Ausheva

National Medical Research Center for Oncology

ORCID: 0000-0002-7073-9463

Optimal prevention of VTE in cancer surgery patients with impaired renal function

Authors:

O.V. Katelnitskaya, A.A. Barashev, T.V. Ausheva

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2024;(1): 119‑126

DOI: 10.17116/hirurgia2024011119

Downloaded: 4

Contact the author

Table of contents

To cite this article:

Katelnitskaya OV, Barashev AA, Ausheva TV. Optimal prevention of VTE in cancer surgery patients with impaired renal function. Pirogov Russian Journal of Surgery. 2024;(1):119‑126. (In Russ.)
https://doi.org/10.17116/hirurgia2024011119

Доказательная гастроэнтерология: pro et contra

Актуальные вопросы педиатрической практики

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Genetically engineered biological therapy for psoriasis in patients with a history of cancer: a literature review and case report. Russian Journal of Clinical Dermatology and Venereology. 2023;(1):57-63

Modern view on postoperative perineal hernias surgical treatment. Russian Journal of Operative Surgery and Clinical Anatomy. 2023;(1):34-40

Multiple linear regression analysis of cancer treatment effectiveness at the level of constituent entities in the Russian Federation. Medical Technologies. Assessment and Choice. 2023;(1):9-26

Postoperative pain assessment in patients with Crohn’s disease. Russian Journal of Evidence-Based Gastroenterology. 2023;(1):37-41

Surgery for lung cancer in elderly and senile patients: a ten-year experience of two centers. P.A. Herzen Journal of Oncology. 2023;(2):11-18

Problems of a comprehensive assessment of the malignancy potential of pancreatic cystic neoplasia using endoscopic ultrasonography and fine needle aspiration puncture. Endoscopic Surgery. 2023;(2):11-18

Caldesmon and tumor growth: prospects for optimizing diagnosis and targeted therapy. Russian Journal of Archive of Pathology. 2023;(2):53-59

Primary spine and spinal cord tumours and pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2023;(2):88-94

Results of surgical treatment in patients with critical ischemia of the lower limbs and complications of endovascular interventions. Russian Journal of Cardiology and Cardiovascular Surgery. 2017;(1):47-50

Early and Long-term results of surgical treatment of combined carotid and coronary atherosclerotic lesion. Russian Journal of Cardiology and Cardiovascular Surgery. 2017;(1):22-27

Despite notable progress in the prevention of venous thromboembolic complications (VTE) and its widespread use in recent decades, mortality in cancer patients from VTE is still second only to the main disease. Some features and limitations in cancer patients, such as a decrease in kidney function and platelet count, an increased risk of bleeding, and the difficulty of monitoring the adequacy and safety of thromboprophylaxis, as well as the use of aggressive chemotherapy, determine the need for more effective and safer ways to solve the problem of VTE. Also, in the case of surgical interventions in such patients, the need for preoperative thromboprophylaxis raises new challenges for doctors. The article presents a review of the issue using a clinical case.

Keywords:

venous thromboembolic events

oncology

surgical treatment

impaired renal function

fondaparinux

Authors:

O.V. Katelnitskaya

National Medical Research Center for Oncology

ORCID: 0000-0002-7777-9943

A.A. Barashev

National Medical Research Center for Oncology

ORCID: 0000-0002-7242-6938

T.V. Ausheva

National Medical Research Center for Oncology

ORCID: 0000-0002-7073-9463

Received:

22.10.2023

Accepted:

12.11.2023

List of references:

Khorana AA, Mackman N, Falanga A, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. https://doi.org/10.1038/s41572-022-00336-y
Amin A, Neuman WR, Lingohr-Smith M, et al. Venous Thromboembolism Prophylaxis and Risk for Acutely Medically Ill Patients Stratified by Different Ages and Renal Disease Status. Clin Appl Thromb Hemost. 2019;25:1-9. https://doi.org/110.1177/1076029618823287
Seliverstov EI, Lobastov KV, Ilyukhin EA, et al. Prevention, Diagnostics and Treatment of Deep Vein Thrombosis Russian Experts Consensus. Flebologiya. 2023;17(3):152-296. (In Russ.). https://doi.org/10.17116/flebo202317031152
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-266.
Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2005;67:2089-1007
Janus N, Launay-Vacher V, Byloos E, et al. Cancer and renal insufficiency results of the BIRMA study. British Journal of Cancer. 2010;103:1815-1821. https://doi.org/10.1038/sj.bjc.6605979
Elalamy I, Canon JL, Bols A, et al. Thrombo-Embolic Events in Cancer Patients with Impaired Renal Function. J Blood Disorders Transf. 2014;5:4. https://doi.org/10.4172/2155-9864.1000202
Dimitriadi SN, Kit OI, Franciyanc EM, et al. Diagnosticheskaya znachimost’ biomarkerov v diagnostike ostrogo povrezhdeniya pochek posle rezekcii pochki po povodu lokalizovannogo raka pochki. V knige: Tezisy X S»ezda onkologov Rossii. Nizhniy Novgorod; 2019. (In Russ.).
Launay-Vacher V, Spano JP, et al; Renal Insufficiency and Anticancer Medications (IRMA) Study Group. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009;70(2):124-133. https://doi.org/10.1016/j.critrevonc.2008.09.012
Dentali F, Riva N, Gianni M, et al. Prevalence of renal failure and use of thromboembolic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. Thromb Res. 2008;123(1):67-71. https://doi.org/10.1016/j.thromres.2008.01.009
Ageno W, Riva N, Noris P, et al; FONDAIR study group. Safety and efficacy of low-dose fondaparinux (1.5 mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. J Thromb Haemost. 2012;10(11):2291-2297. https://doi.org/10.1111/j.1538-7836.2012.04908.x
Mismetti P, Samama CM, Rosencher N, et al; PROPICE Study Group. Venous thromboembolism prevention with fondaparinux 1.5 mgin renally impaired patients undergoing major orthopaedic surgery. Thromb Haemostas. 2012;107(6):1151-1160.
Chen PB, Wang J, Wang L, et al. Study on the safety and effectiveness of low-dose vs. regular-dose fondaparinux in preventing venous thromboembolism prophylaxis following total knee arthroplasty. Front Cardiovasc Med. 2023;10:1195322. https://doi.org/10.3389/fcvm.2023.1195322
Wang L, Su Z, Xie C, et al. Efficacy and safety of fondaparinux in preventing venous thromboembolism in Chinese cancer patients: a single-arm, multicenter, retrospective study. Front Oncol. 2023;13:1165437. https://doi.org/10.3389/fonc.2023.1165437
Tokuhara K, Matsushima H, Ueyama Y, et al. Efficacy and safety of thromboembolism prophylaxis with fondaparinux in Japanese colorectal cancer patients undergoing laparoscopic surgery: A phase II study. Int J Surg. 2017;42:203-208. https://doi.org/10.1016/j.ijsu.2017.04.014
Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Arikstra P N015462|01, dostupno na 20.10.23 Gosudarstvennyj reestr lekarstvennyh sredstv (rosminzdrav.ru).

Close metadata